Biotech Stock Roundup VNDA, JAZZ Up on Updates, NVAX Suffers Setback More
VNDA Stock | USD 4.85 0.03 0.62% |
About 52% of Vanda Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Vanda Pharmaceuticals suggests that many traders are impartial. The current market sentiment, together with Vanda Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Vanda Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Vanda |
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
Read at zacks.com
Vanda Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Vanda Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vanda Pharmaceuticals Fundamental Analysis
We analyze Vanda Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vanda Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vanda Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Vanda Pharmaceuticals is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Vanda Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vanda Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Vanda Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vanda Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Vanda Pharmaceuticals Related Equities
PHAT | Phathom Pharmaceuticals | 5.59 | ||||
KZR | Kezar Life | 4.41 | ||||
RLAY | Relay Therapeutics | 3.39 | ||||
TECH | Bio Techne | 3.23 | ||||
LEGN | Legend Biotech | 3.02 | ||||
LQDA | Liquidia Technologies | 1.57 | ||||
BPMC | Blueprint Medicines | 1.35 | ||||
PCVX | Vaxcyte | 1.33 | ||||
REPL | Replimune | 0.48 | ||||
BMRN | Biomarin Pharmaceutical | 0.36 | ||||
CYTK | Cytokinetics | 0.34 | ||||
RCUS | Arcus Biosciences | 0.46 | ||||
RVMD | Revolution Medicines | 0.63 | ||||
TIL | Instil Bio | 1.26 | ||||
GPCR | Structure Therapeutics | 1.53 | ||||
ANNX | Annexon | 1.64 | ||||
TSVT | 2Seventy Bio | 1.69 | ||||
NUVB | Nuvation Bio | 1.73 | ||||
CNTB | Connect Biopharma | 2.48 | ||||
STOK | Stoke Therapeutics | 4.09 | ||||
CGEM | Cullinan Oncology | 7.10 |
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |